VXA-CoV2-1 Uses, Dosage, Side Effects and more
VXA-CoV2-1 is a non-replicating adenoviral vector-based oral tableted vaccine candidate that expresses a SARS-CoV-2 antigen and dsRNA adjuvant. This oral vaccine aims to induce immunogenicity through induction of potent serum neutralizing antibodies to the SARS-CoV-2 spike protein, induction of mucosal immune responses, and induction of T-cell responses to both vaccine antigens of the SARS-CoV-2 nucleocapsid and spike proteins.
| Trade Name | VXA-CoV2-1 |
| Generic | VXA-CoV2-1 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
